Vera Therapeutics, Inc. Research and Development Expense
Vera Therapeutics, Inc. (VERA) reported Research and Development Expense of $60.08 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-10
- Vera Therapeutics, Inc. research and development expense for the quarter ending 2026-06-30 was $60.08M, a 3.24% increase year-over-year.
- Vera Therapeutics, Inc. research and development expense for the quarter ending 2026-03-31 was $86.01M, a 108.37% increase year-over-year.
- Vera Therapeutics, Inc. research and development expense for the quarter ending 2025-12-31 was $59.31M, a 77.86% increase year-over-year.
- Vera Therapeutics, Inc. research and development expense for the quarter ending 2025-09-30 was $56.47M, a 40.08% increase year-over-year.
- Vera Therapeutics, Inc. research and development expense for fiscal 2025 was $215.26M, a 70.61% increase from fiscal 2024.
- Vera Therapeutics, Inc. research and development expense for fiscal 2024 was $126.17M, a 61.29% increase from fiscal 2023.
- Vera Therapeutics, Inc. research and development expense for fiscal 2023 was $78.22M, a 13.38% increase from fiscal 2022.
- Vera Therapeutics, Inc. research and development expense for fiscal 2022 was $68.99M, a 206.85% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $60.08M 10-Q · filed 2026-08-10 | $146.09M 10-Q · filed 2026-08-10 | $205.40M derived: sum of 3 quarters · filed 2026-08-10 | $261.87M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $86.01M 10-Q · filed 2026-05-07 | $145.32M derived: sum of 2 quarters · filed 2026-05-07 | $201.79M derived: sum of 3 quarters · filed 2026-05-07 | $259.99M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $59.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $115.78M derived: sum of 2 quarters · filed 2026-02-26 | $173.98M derived: sum of 3 quarters · filed 2026-08-10 | $215.26M 10-K · filed 2026-02-26 |
| 2025-09-30 | $56.47M 10-Q · filed 2025-11-05 | $114.67M derived: sum of 2 quarters · filed 2026-08-10 | $155.95M 10-Q · filed 2025-11-05 | $189.29M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $58.20M 10-Q · filed 2026-08-10 | $99.47M 10-Q · filed 2026-08-10 | $132.82M derived: sum of 3 quarters · filed 2026-08-10 | $173.13M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $41.28M 10-Q · filed 2026-05-07 | $74.63M derived: sum of 2 quarters · filed 2026-05-07 | $114.94M derived: sum of 3 quarters · filed 2026-05-07 | $144.25M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $33.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $73.66M derived: sum of 2 quarters · filed 2026-02-26 | $102.97M derived: sum of 3 quarters · filed 2026-02-26 | $126.17M 10-K · filed 2026-02-26 |
| 2024-09-30 | $40.31M 10-Q · filed 2025-11-05 | $69.63M derived: sum of 2 quarters · filed 2025-11-05 | $92.83M 10-Q · filed 2025-11-05 | $113.61M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $29.31M 10-Q · filed 2025-08-05 | $52.51M 10-Q · filed 2025-08-05 | $73.30M derived: sum of 3 quarters · filed 2026-02-26 | $89.40M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $23.20M 10-Q · filed 2025-05-07 | $43.98M derived: sum of 2 quarters · filed 2026-02-26 | $60.09M derived: sum of 3 quarters · filed 2026-02-26 | $76.32M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $20.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $36.88M derived: sum of 2 quarters · filed 2026-02-26 | $53.12M derived: sum of 3 quarters · filed 2026-02-26 | $78.22M 10-K · filed 2026-02-26 |
| 2023-09-30 | $16.10M 10-Q · filed 2024-11-07 | $32.33M derived: sum of 2 quarters · filed 2024-11-07 | $57.44M 10-Q · filed 2024-11-07 | $84.11M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $16.23M 10-Q · filed 2024-08-08 | $41.34M 10-Q · filed 2024-08-08 | $68.02M derived: sum of 3 quarters · filed 2024-08-08 | $87.67M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $25.11M 10-Q · filed 2024-05-10 | $51.78M derived: sum of 2 quarters · filed 2024-05-10 | $71.44M derived: sum of 3 quarters · filed 2024-05-10 | $81.55M derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | $26.68M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $46.33M derived: sum of 2 quarters · filed 2024-03-27 | $56.44M derived: sum of 3 quarters · filed 2024-03-27 | $68.99M 10-K · filed 2024-03-27 |
| 2022-09-30 | $19.66M 10-Q · filed 2023-11-09 | $29.77M derived: sum of 2 quarters · filed 2023-11-09 | $42.32M 10-Q · filed 2023-11-09 | $55.07M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $10.11M 10-Q · filed 2023-08-10 | $22.66M 10-Q · filed 2023-08-10 | $35.41M derived: sum of 3 quarters · filed 2023-08-10 | $38.98M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $12.55M 10-Q · filed 2023-05-11 | $25.30M derived: sum of 2 quarters · filed 2023-05-11 | $28.87M derived: sum of 3 quarters · filed 2023-05-11 | $32.10M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $12.75M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $16.32M derived: sum of 2 quarters · filed 2023-03-28 | $19.55M derived: sum of 3 quarters · filed 2023-03-28 | $22.48M 10-K · filed 2023-03-28 |
| 2021-09-30 | $3.56M 10-Q · filed 2022-11-09 | $6.80M derived: sum of 2 quarters · filed 2022-11-09 | $9.73M 10-Q · filed 2022-11-09 | $49.58M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $3.23M 10-Q · filed 2022-08-10 | $6.17M 10-Q · filed 2022-08-10 | $46.01M derived: sum of 3 quarters · filed 2022-08-10 | $47.98M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $2.93M 10-Q · filed 2022-05-16 | $42.78M derived: sum of 2 quarters · filed 2022-05-16 | $44.74M derived: sum of 3 quarters · filed 2022-05-16 | $46.70M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $39.84M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $41.81M derived: sum of 2 quarters · filed 2022-03-28 | $43.77M derived: sum of 3 quarters · filed 2022-03-28 | $45.21M 10-K · filed 2022-03-28 |
| 2020-09-30 | $1.97M 10-Q · filed 2021-11-10 | $3.92M derived: sum of 2 quarters · filed 2021-11-10 | $5.36M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $1.95M 10-Q · filed 2021-08-16 | $3.39M 10-Q · filed 2021-08-16 | ||
| 2020-03-31 | $1.44M 10-Q · filed 2021-06-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |